Incidence and Outcomes of Cystoid Macular Edema after Descemet Membrane Endothelial Keratoplasty (DMEK) and DMEK Combined with Cataract Surgery
PURPOSE: To investigate the incidence and outcomes of cystoid macular edema (CME) after Descemet membrane endothelial keratoplasty (DMEK) alone and DMEK combined with cataract surgery (DMEK triple).
MATERIALS AND METHODS: A retrospective chart review was performed for patients who underwent DMEK and DMEK triple between January 2014 and March 2018 at two tertiary hospitals. Patients with minimum of 6 months of follow-up were included. Logistic regression analysis was used to identify potential risk factors for CME including gender, age, glaucoma, uveitis, epiretinal membrane, diabetes mellitus, iridotomy, and rebubbling.
RESULTS: 09 eyes of 193 patients who underwent DMEK (124 eyes) and DMEK triple (85 eyes) were included. The 6-month incidence of CME was 3.8% (8/209) for all cases, 2.4% (2/85) for DMEK triple, and 4.8% (6/124) for DMEK alone. CME was treated with topical prednisolone acetate 1% and nepafenac four times daily, and/or periocular triamcinolone acetonide, with resolution in all cases. On average, CME was detected 8.9 ± 2.1 weeks postoperatively, with a mean time to resolution of 4.1 ± 1.7 months. The 6-month best-corrected distance visual acuity of eyes that developed CME was not significantly different compared to eyes that did not develop CME (0.17 ± 0.15 logMAR vs. 0.23 ± 0.27 logMAR; p = .76). On logistic regression analysis, no risk factors for developing CME were identified.
CONCLUSIONS: The incidence of CME after DMEK was low and not associated with decreased long-term visual acuity. Most cases of CME occurred between 1 and 3 months postoperatively. Predictive factors for CME after DMEK require further study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Current eye research - 46(2021), 5 vom: 01. Mai, Seite 678-682 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ching, Geoffrey [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.12.2021 Date Revised 24.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/02713683.2020.1818260 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314381732 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314381732 | ||
| 003 | DE-627 | ||
| 005 | 20231225152615.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02713683.2020.1818260 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314381732 | ||
| 035 | |a (NLM)32865037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ching, Geoffrey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and Outcomes of Cystoid Macular Edema after Descemet Membrane Endothelial Keratoplasty (DMEK) and DMEK Combined with Cataract Surgery |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2021 | ||
| 500 | |a Date Revised 24.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To investigate the incidence and outcomes of cystoid macular edema (CME) after Descemet membrane endothelial keratoplasty (DMEK) alone and DMEK combined with cataract surgery (DMEK triple) | ||
| 520 | |a MATERIALS AND METHODS: A retrospective chart review was performed for patients who underwent DMEK and DMEK triple between January 2014 and March 2018 at two tertiary hospitals. Patients with minimum of 6 months of follow-up were included. Logistic regression analysis was used to identify potential risk factors for CME including gender, age, glaucoma, uveitis, epiretinal membrane, diabetes mellitus, iridotomy, and rebubbling | ||
| 520 | |a RESULTS: 09 eyes of 193 patients who underwent DMEK (124 eyes) and DMEK triple (85 eyes) were included. The 6-month incidence of CME was 3.8% (8/209) for all cases, 2.4% (2/85) for DMEK triple, and 4.8% (6/124) for DMEK alone. CME was treated with topical prednisolone acetate 1% and nepafenac four times daily, and/or periocular triamcinolone acetonide, with resolution in all cases. On average, CME was detected 8.9 ± 2.1 weeks postoperatively, with a mean time to resolution of 4.1 ± 1.7 months. The 6-month best-corrected distance visual acuity of eyes that developed CME was not significantly different compared to eyes that did not develop CME (0.17 ± 0.15 logMAR vs. 0.23 ± 0.27 logMAR; p = .76). On logistic regression analysis, no risk factors for developing CME were identified | ||
| 520 | |a CONCLUSIONS: The incidence of CME after DMEK was low and not associated with decreased long-term visual acuity. Most cases of CME occurred between 1 and 3 months postoperatively. Predictive factors for CME after DMEK require further study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DMEK | |
| 650 | 4 | |a DMEK triple | |
| 650 | 4 | |a Descemet membrane endothelial keratoplasty | |
| 650 | 4 | |a cystoid macular edema | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Benzeneacetamides |2 NLM | |
| 650 | 7 | |a Ophthalmic Solutions |2 NLM | |
| 650 | 7 | |a Phenylacetates |2 NLM | |
| 650 | 7 | |a nepafenac |2 NLM | |
| 650 | 7 | |a 0J9L7J6V8C |2 NLM | |
| 650 | 7 | |a prednisolone acetate |2 NLM | |
| 650 | 7 | |a 8B2807733D |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 650 | 7 | |a Triamcinolone Acetonide |2 NLM | |
| 650 | 7 | |a F446C597KA |2 NLM | |
| 700 | 1 | |a Covello, Albert T |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Steven S |e verfasserin |4 aut | |
| 700 | 1 | |a Holland, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a McCarthy, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Ritenour, Rusty |e verfasserin |4 aut | |
| 700 | 1 | |a Iovieno, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Yeung, Sonia N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current eye research |d 1987 |g 46(2021), 5 vom: 01. Mai, Seite 678-682 |w (DE-627)NLM012607460 |x 1460-2202 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2021 |g number:5 |g day:01 |g month:05 |g pages:678-682 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02713683.2020.1818260 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2021 |e 5 |b 01 |c 05 |h 678-682 | ||